Jay Pepose - 01 Jul 2022 Form 4 Insider Report for Ocuphire Pharma, Inc. (IRD)

Transaction snapshot 2 facts
Issuer context 1 fact
SEC evidence 5 facts
Form type
4
Filing time
06 Jul 2022, 17:36:24 UTC
Previous filing
15 Jun 2022
Next filing
12 Jan 2023
SEC filing
View on sec.gov
Reporting owner 2 facts
Signature
/s/ Emily J. Johns, by Power of Attorney

Key filing fact

Jay Pepose filed Form 4 for Ocuphire Pharma, Inc. (IRD) on 06 Jul 2022.

Key facts

  • This page summarizes Jay Pepose's Form 4 filing for Ocuphire Pharma, Inc. (IRD).
  • 1 reported transaction and 0 derivative rows are listed below.
  • Filing timestamp: 06 Jul 2022, 17:36.

Change

  • Previous filing in this sequence was filed on 15 Jun 2022.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Reported transactions

OCUP transaction

Common Stock

Award

Transaction value
Shares
+9,900
Change %
+43%
Price
Shares after
32,894
Date
01 Jul 2022
Ownership
Direct
Footnotes
F1
* indicates a reported price that failed the local validity check.

Explanation of Responses:

Id Content
F1 The Reporting Person was granted shares of common stock in lieu of cash for board services for the second half of 2022. The number of shares was determined by dividing (A) the aggregate amount of the retainer to be earned for board services for such period, by (B) the average fair market value of a share of common stock for the 30 consecutive trading days ending on and including the last trading day prior to the grant date (rounded down to the nearest whole share). The average fair market value was $2.02 per share, the average of the closing price of the common stock for the 30 consecutive trading days prior to July 1, 2022.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .